PIK3CA activating mutations: A discordant role in early versus advanced hormone-dependent estrogen receptor-positive breast cancer?

Journal of Clinical Oncology

Volumn 32, Issue 27, 2014, Pages 2932-2934

  Mayer, Ingrid A ^a   Arteaga, Carlos L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B; TUMOR MARKER;

ANOIKIS; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG RESISTANCE; EDITORIAL; ENZYME ACTIVE SITE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE AMPLIFICATION; GENE MUTATION; HUMAN; NONHUMAN; PHENOTYPE; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; FEMALE; GENETICS; MUTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84907199373     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.9591     Document Type: Editorial

References (27)

1. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562, 2009
2. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012
3. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573, 2005
4. Isakoff SJ, Engelman JA, Irie HY, et al: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65: 10992-11000, 2005
5. Eichhorn PJ, Gili M, Scaltriti M, et al: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68: 9221-9230, 2008
6. Chakrabarty A, Rexer BN, Wang SE, et al: H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 29: 5193-5203, 2010
7. Pérez-Tenorio G, Alkhori L, Olsson B, et al: PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13: 3577-3584, 2007
8. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091, 2008
9. Loi S, Haibe-Kains B, Majjaj S, et al: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 107: 10208-10213, 2010
10. Ellis MJ, Lin L, Crowder R, et al: Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119: 379-390, 2010
11. Miller TW, Hennessy BT, González-Angulo AM, et al: Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120: 2406-2413, 2010
12. Sabine VS, Crozier C, Brookes CL, et al: Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 32: 2951-2958, 2014
13. van de Velde CJ, Rea D, Seynaeve C, et al: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial. Lancet 377: 321-331, 2011
14. Kalinsky K, Jacks LM, Heguy A, et al: PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15: 5049-5059, 2009
15. Bachelot T, Bourgier C, Cropet C, et al: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 30: 2718-2724, 2012
16. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520-529, 2012
17. Hortobagyi GN, Piccart-Gebhart MJ, Rugo HS, et al: Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive (HR+), HER2-negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol 31: 9s, 2013 (suppl; abstr LBA509)
18. Crowder RJ, Phommaly C, Tao Y, et al: PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 69: 3955-3962, 2009
19. Fox EM, Kuba MG, Miller TW, et al: Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res 15: R55, 2013
20. Mayer IA, Abramson VG, Isakoff SJ, et al: Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 32: 1202-1209, 2014
21. Dupont Jensen J, Laenkholm AV, Knoop A, et al: PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17: 667-677, 2011
22. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al: PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10: 1093-1101, 2011
23. Juric D, Rodon J, Gonzalez-Angulo AM, et al: Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Cancer Res 72, 2012 (suppl 1; abstr CT-01)
24. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909, 2005
25. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009
26. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010
27. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010